×

Perseon to Present at Rodman & Renshaw 17th Annual Global Investment Conference

SALT LAKE CITY, Sept. 8, 2015 (GLOBE NEWSWIRE) -- Perseon Corporation (NASDAQ:PRSN) ("Perseon" or the "Company"), a leading provider of medical systems that utilize energy to treat cancer, today announced that management will present at the Rodman & Renshaw 17th Annual Global Investment Conference being held at The St. Regis Hotel, New York City. Clint Carnell, Chief Executive Officer, will provide an overview of Perseon and its strategy at 11:40 a.m. Eastern time on Thursday, September 10, 2015.

Perseon's presentation will be webcast live and archived for 90 days on the Events and Presentations page at http://perseonmedical.com.

About Perseon

Perseon Corporation invests its resources in fighting humanity's worst disease: cancer. Perseon's people are dedicated to finding innovative technologies and means to deliver energy solutions to healthcare providers and patients around the world. MicroThermX® treats soft tissue tumors with precision-focused energy, expanding the options and broadening the opportunities for cancer treatment.

Forward-Looking Statements

Statements contained in this press release that are not historical facts, including statements relating to our focus on microwave ablation to create stockholder value and pursuit of our strategic plans are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties, including the risk that for a variety of reasons we may not be able to execute on our strategic plans, and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.

CONTACT: Tricia Ross Financial Profiles 310-622-8226 tross@finprofiles.com

Source:Perseon Corporation